Cytokinetics Shares Sold by Melqart Asset Management

Institutional investor reduces stake in biopharmaceutical company

Mar. 14, 2026 at 11:08am

Got story updates? Submit your updates here. ›

Melqart Asset Management UK Ltd reduced its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 40.9% during the 3rd quarter, according to the company's recent SEC filing. The institutional investor owned 783,774 shares of the biopharmaceutical company's stock after selling 542,945 shares during the period.

Why it matters

Cytokinetics is a late-stage biopharmaceutical company focused on developing novel small-molecule therapeutics that modulate muscle function. The reduction in Melqart's stake could signal a shift in investor sentiment or portfolio rebalancing, which could impact the company's stock price and future funding.

The details

Melqart Asset Management UK Ltd reduced its stake in Cytokinetics by 40.9% during the 3rd quarter, selling 542,945 shares. The institutional investor now owns 783,774 shares of the biopharmaceutical company, which accounts for 5.7% of its investment portfolio and makes it the 4th biggest holding.

  • Melqart Asset Management UK Ltd reduced its stake in Cytokinetics during the 3rd quarter of 2026.

The players

Melqart Asset Management UK Ltd

An institutional investor that reduced its stake in Cytokinetics, Incorporated.

Cytokinetics, Incorporated

A late-stage biopharmaceutical company focused on developing novel small-molecule therapeutics that modulate muscle function.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Melqart's stake in Cytokinetics could signal a shift in investor sentiment or portfolio rebalancing, which could impact the company's stock price and future funding. However, Cytokinetics remains a late-stage biopharmaceutical company with a focus on developing novel muscle-modulating therapies, which could continue to attract investor interest.